Sanofi said the results are strong enough to support a new indication in the US and EU for Libtayo, a PD-1 inhibitor that is already FDA-approved in advanced cutaneous squamous cell carcinoma.

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.